The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 15, 2005
Filed:
Mar. 31, 1998
Patricia A. Billing-medel, Grayslake, IL (US);
Maurice Cohen, Highland Park, IL (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Deerfield, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Mark A. Hayden, Ingleside, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Libertyville, IL (US);
Jon D. Kratochvil, Wildwood, MO (US);
John C. Russell, Pleasant Prairie, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Patricia A. Billing-Medel, Grayslake, IL (US);
Maurice Cohen, Highland Park, IL (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Deerfield, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Mark A. Hayden, Ingleside, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Libertyville, IL (US);
Jon D. Kratochvil, Wildwood, MO (US);
John C. Russell, Pleasant Prairie, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Abbott Laboratories, Abbott Park, IL (US);
Abstract
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS141 and transcribed from GI tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS141-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS141 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.